| 卫迎朝,鲁金乐,张静,等.疏肝消瘿方联合西药治疗肝郁痰凝型甲状腺癌术后临床观察[J].安徽医药,2026,30(7):1452-1456. |
| 疏肝消瘿方联合西药治疗肝郁痰凝型甲状腺癌术后临床观察 |
| Clinical observation of Shugan Xiaoying prescription combined with Western Medicine in the treatment of patients with thyroid cancer after operation of liver-depression phlegm coagulation syndrome |
| |
| DOI：10.3969/j.issn.1009-6469.2026.07.035 |
| 中文关键词: 甲状腺肿瘤 疏肝消瘿方 碘 -131 甲状腺素 临床疗效 |
| 英文关键词: Thyroid neoplasms Shugan Xiaoying formula Iodine-131 Thyroxine Clinical efficacy |
| 基金项目:河北省中医药类科学研究课题计划项目( 2023244) |
|
| 摘要点击次数: 252 |
| 全文下载次数: 61 |
| 中文摘要: |
| 目的观察疏肝消瘿方联合碘 -131和甲状腺素治疗肝郁痰凝证甲状腺癌的临床效果。方法前瞻性选择 2022年 8月至 2023年 12月保定市第一中心医院肝郁痰凝证甲状腺癌术后病人 110例为研究对象，随机数字表法分为对照组( 55例，给予西医治疗:碘-131清钾联合左旋甲状腺素钠片治疗)、联合治疗组( 55例，在对照组的基础上给予疏肝消瘿方治疗)。记录两组临床疗效及不良反应发生情况，并对比两组病人治疗前后甲状腺激素、甲状腺激素相关抗体、相关生长因子情况。结果联合治疗组总有效率(96.36%)高于对照组( 81.82%)差异有统计学意义( P<0.05)。治疗后，两组病人 FT3、FT4、血清促甲状腺激素受体抗体( TRAb)、抗甲状腺球蛋白抗体( TgAb)、甲，状腺过氧化物酶抗体( TPOAb)、血清肿瘤特异性生长因子( TSGF)、碱性成纤维细胞生长因子( bFGF)、血管内皮生长因子( VEGF)水平均降低，且联合治疗组更低( P<0.05)；促甲状腺激素( TSH)水平升高且联合治疗组高于对照组( P<0.05)。两组不良反应发生情况差异无统计学意义( P>0.05)。结论疏肝消瘿方联合碘 -131和甲状腺素可改善肝郁痰凝证甲状腺癌术后病人甲状腺激素、甲状腺激素相关抗体、相关生长因子水平，提高疾病治疗效果，安全性更佳。 |
| 英文摘要: |
| Objective To observe the clinical effect of Shugan Xiaoying prescription combined with Iodine-131 and thyroxine in treating thyroid cancer with liver-depression phlegm coagulation.Methods Prospective selection one hundred and ten postoperative patients with liver depression and phlegm coagulation syndrome and thyroid cancer at Baoding Frist Central Hospital from August 2022to December 2023 as the research subjects. They were randomly divided into a control group (55 cases, treated with Western Medicine:iodine-131 potassium combined with levothyroxine sodium tablets) and a combination treatment group (55 cases, treated with Shugan Xiaoying formula on the basis of the control group) using a random number table method. The clinical efficacy and incidence of adversereactions between two groups were recorded, and the levels of thyroid hormones, thyroid hormone related antibodies, and related growthfactors were compared.Results The total effective rate of the combined treatment group (96.36%) was higher, and the difference was statistically significant (P<0.05). After treatment, the serum levels of FT3, FT4, thyrotropin receptor antibody (TRAb), antithyroglobulinantibody (TgAb), thyroid peroxidase antibody (TPOAb), basic fibroblast growth factor (bFGF), tumor specific growth factor (TSGF), andvascular endothelial growth factor (VEGF) in both groups decreased, and the combined treatment group were lower, the difference wassignificant (P<0.05); the level of thyroid-stimulating hormone (TSH) in the combined treatment group was higher, the difference was sig-nificant (P<0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P>0.05). Conclusion Shugan Xiaoying prescription combined with iodine-131 and thyroxine can improve the levels of thyroid hormone, thy-roid hormone-related antibodies and related growth factors in patients with thyroid cancer after operation with liver-stagnation spittoon syndrome, and improve the therapeutic effect and better safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
